The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 13, 2012

Filed:

Sep. 08, 2009
Applicants:

Suresh C. Srivastava, Burlington, MA (US);

Divya Pandey, Lucknow, IN;

Satya P Bajpai, Lucknow, IN;

Naveen P Srivastava, Burlington, MA (US);

Inventors:

Suresh C. Srivastava, Burlington, MA (US);

Divya Pandey, Lucknow, IN;

Satya P Bajpai, Lucknow, IN;

Naveen P Srivastava, Burlington, MA (US);

Assignee:

ChemGenes Corporation, Wilmigton, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/00 (2006.01); C07H 19/20 (2006.01); C07H 19/10 (2006.01); C07H 19/048 (2006.01);
U.S. Cl.
CPC ...
Abstract

Novel technology for RNA synthesis in the reverse direction, involving a new class of products, 3'-DMT-5'-CE ribonucleoside phosphoramidites and 3′-DMT-5'-succinyl ribonucleoside solid supports, with per step coupling efficiency surpassing 99% in the RNA synthesis. This leads to high purity RNA. Examples of a large number of 20-21 mers and a few examples of long chain oligonucleotides are demonstrated. The data indicates dramatic improvement in coupling efficiency per step during oligonucleotide synthesis using the reverse RNA monomers (5′→′ direction) as compared to 3′-CE ribonucleoside phosphoramidites used in the conventional method of RNA synthesis (3′→5′ direction). The new process requires shorter coupling cycle time, approx. 4 minutes as compared to approx. 10 minutes using conventional RNA synthesis method (3′→5′ direction). Furthermore, almost complete absence of M+1 impurities in the reverse RNA synthesis methodology were observed, even when the last phosphoramidite was a macromolecule. The process resulted in very high purity 3′-modified oligonucleotides after HPLC purification. As a result of high purity of synthesized RNA and clean introduction of various 3′-end modified RNA requiring long chain ligands, chromophores, fluorophores and quenchers, this method of RNA synthesis is expected to be a very useful method of choice for therapeutic grade RNA. The novel phosphoramidites of this invention, Rev-A-n-bz, Rev-C-n-bz, Rev-C-n-ac, Rev-G-n-ac and Rev-rU show HPLC purity greater than 98% andP NMR purity greater than 99.5%.


Find Patent Forward Citations

Loading…